Journal of Vaccines & Vaccination

Rita Hörlein

Publications

• Research Article
  Genomic CpG Enrichment of Oncolytic Parvoviruses as a Potent Anticancer Vaccination Strategy for the Treatment of Pancreatic Adenocarcinoma
  Author(s): Svitlana P. Grekova, Marc Aprahamian, Nathalia A. Giese, Gaetan Bour, Thomas Giese, Annabel Grewenig, Barbara Leuchs, Rita Hörlein, Anette Heller, Assia L. Angelova, Jean Rommelaere and Zahari Raykov Svitlana P. Grekova, Marc Aprahamian, Nathalia A. Giese, Gaetan Bour, Thomas Giese, Annabel Grewenig, Barbara Leuchs, Rita Hörlein, Anette Heller, Assia L. Angelova, Jean Rommelaere and Zahari Raykov
  
  Objective: For quite a long time oncolytic viruses (OVs) have been regarded merely as specific tumor cell killers, while disregarding the fact that all oncolytic activities take place in the context of a functional immune system. Oncolytic parvoviruses (PV) represent non-pathogenic, naturally oncolytic (non-modified), animal (rodent) viruses with a tropism that extends to a number of transformed human cells. Our recent work using various animal models substantiates the contention that H-1PV acts as both an oncolytic agent and an adjuvant, by direct cytoreduction in the tumor and bystander antitumor immunity. ImmunostimulatoryCpG motifs were incorporated into the singlestranded DNA genome of H-1PV and our current objective was to test whether the CpG-armed virus was in possession of an enhanced adjuvant capacity. Methods: The immunogenic potential of the CpG-enriched parvoviral derivat.. View More»
  DOI: 10.4172/2157-7560.1000227

  Abstract PDF